- Previous Close
39.75 - Open
39.85 - Bid 39.75 x --
- Ask 39.80 x --
- Day's Range
39.75 - 39.90 - 52 Week Range
39.55 - 4,335.00 - Volume
59,945 - Avg. Volume
91,087 - Market Cap (intraday)
4.019B - Beta (5Y Monthly) 0.28
- PE Ratio (TTM)
16.58 - EPS (TTM)
2.40 - Earnings Date Apr 30, 2025 - May 7, 2025
- Forward Dividend & Yield 2.00 (5.03%)
- Ex-Dividend Date Jul 4, 2024
- 1y Target Est
42.00
Nang Kuang Pharmaceutical Co., Ltd., together with its subsidiary, engages in the manufacturing, processing, trading, import, and export of pharmaceuticals and medical devices in Taiwan, China, Japan, the United States, and internationally. The company offers ready to use injections, such as prefilled syringe injection and premixed IV infusion; anti-aging and preventive medicines; chemotherapy and oncology products; and non-PVC IV infusion bags. It also provides various products in the areas of cardiovascular, gastrointestinal, nervous, musculo-skeletal, and respiratory system, as well as in alimentary and metabolism, blood, antineoplastic and immunomodulatory, dermatological, genito-urinary and sex hormone, systemic hormone and antibacterial, cosmetics, and hospital solutions. In addition, the company is involved in trading of pharmaceuticals. Nang Kuang Pharmaceutical Co., Ltd. was founded in 1963 and is headquartered in Tainan City, Taiwan.
www.nangkuang.com.twRecent News: 1752.TW
View MorePerformance Overview: 1752.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1752.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1752.TW
View MoreValuation Measures
Market Cap
4.02B
Enterprise Value
4.35B
Trailing P/E
16.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.83
Price/Book (mrq)
1.66
Enterprise Value/Revenue
1.98
Enterprise Value/EBITDA
8.86
Financial Highlights
Profitability and Income Statement
Profit Margin
11.06%
Return on Assets (ttm)
5.06%
Return on Equity (ttm)
10.14%
Revenue (ttm)
2.2B
Net Income Avi to Common (ttm)
243.41M
Diluted EPS (ttm)
2.40
Balance Sheet and Cash Flow
Total Cash (mrq)
301.54M
Total Debt/Equity (mrq)
26.35%
Levered Free Cash Flow (ttm)
-165.25M